Aimmune Therapeutics

99 articles with Aimmune Therapeutics

• Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting

  2/4/2019

  Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy, and peanut allergy at the 2019 American Academy of Asthma, Allergy and Immunology (AAAAI) Annual Meeting, taking place February 22–25 in San Francisco.

• Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer

  1/18/2019

  Proven Pharmaceutical Leader Brings Deep, Global Experience with Successful Product Launches, Commercialization and Strategic Planning

• 

  Aimmune’s Peanut Allergy Treatment Delayed as Government Shutdown Continues

  1/15/2019

  The partial government shutdown has entered day 24 and the pharma and medtech industry is beginning to feel the impact even more, particularly as the U.S. Food and Drug Administration grows more incapable of reviewing some medications for approval.

• Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement

  1/4/2019

  Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading global investment firm

• Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th

  1/2/2019

  Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Jayson Dallas, M.D., will present a company overview at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019, at 3:00 p.m. Pacific Time.

• Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17

  12/21/2018

  Aimmune Therapeutics, Inc. announced that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for AR101, an investigational biologic oral immunotherapy for the treatment of peanut allergy in children and adolescents ages 4–17

• Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods

  12/20/2018

  AR201 for Egg Allergy Phase 2 Initiation Planned for 2019

• Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children

  12/19/2018

  Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization), an international, Phase 3 clinical trial of AR101 in peanut-allergic children ages 1–3 years. AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

• 

  Top 9 Really Cool Life Science Discoveries of the Year

  12/11/2018

  It seems like every time we turned around this year, there was an exciting or—on a more visceral level, “Hey, that’s cool!” science story. Here’s a look at the top 9 really cool life science discoveries of the year, from outer space, to peanut allergies, to tortoise genomes.

• Aimmune Therapeutics to Host Investor Symposium on the Future of Treating Peanut Allergy with Leading Expert Allergists on Wednesday, December 12th

  12/6/2018

  Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 12, 2018.

• Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science

  11/28/2018

  Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Science

• 

  Research Roundup for November 21: Early Cancer Diagnosis, Carbs or No Carbs, and Why You Love/Hat...

  11/21/2018

  Even with the Thanksgiving week, there is interesting and exciting research being conducted and published. Here’s a look.
• 

  Aimmune Therapeutics' Peanut Allergy Immunotherapy Looks Promising in Phase III Trial

  11/19/2018

  It is estimated that 2.5 percent of all children in the U.S. might have a peanut allergy. Since 2010, according to the America College of Allergy, Asthma and Immunology, incidence of peanut allergies in children had risen 21 percent in the U.S.

• Landmark PALISADE Trial of AR101 Published in New England Journal of Medicine

  11/18/2018

  Treatment with AR101 significantly increased the amount of peanut protein tolerated and reduced the number and severity of reactions to peanut protein

• 

  Nestlé Increases Stake in Aimmune as Company Eyes Filing for FDA Approval of Peanut Allergy Medicine

  11/13/2018

  As California-based Aimmune prepares to seek regulatory approval for its peanut allergy treatment, AR101, Nestlé Health Science has increased its financial stake in the food allergy prevention-focused company with another $98 million investment.

• Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science

  11/12/2018

  Nestlé Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share

• Aimmune Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Highlights

  11/8/2018

  Recently completed Phase 3 RAMSES study confirms safety profile of AR101 in peanut-allergic children and teens

• Aimmune Therapeutics Announces Presentations at 2018 ACAAI Annual Scientific Meeting

  11/8/2018

  Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on AR101, oral immunotherapy and peanut allergy at the American College of Asthma, Allergy and Immunology (ACAAI) Annual Scientific Meeting, taking place November 15-19, 2018,

• Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors

  11/2/2018

  Pono Life Sciences released a white paper, "Rising Above the Opioid Crisis," that outlines how medical cannabis can help curb America's opioid crisis.

• Aimmune Therapeutics to Participate in Upcoming Investor Conferences

  11/1/2018

  Aimmune is a biopharmaceutical company developing treatments for life-threatening food allergies.